Media headlines about Spring Bank Pharmaceuticals (NASDAQ:SBPH) have trended somewhat positive on Friday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Spring Bank Pharmaceuticals earned a news sentiment score of 0.23 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.9497929988698 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Spring Bank Pharmaceuticals (SBPH) Upgraded by ValuEngine to “Hold” (americanbankingnews.com)
- Spring Bank Pharmaceuticals Inc (SBPH) Given Average Recommendation of “Buy” by Brokerages (americanbankingnews.com)
- Analysts Anticipate Spring Bank Pharmaceuticals Inc (SBPH) to Post -$0.52 EPS (americanbankingnews.com)
- Spring Bank Pharmaceuticals (SBPH) Now Covered by B. Riley (americanbankingnews.com)
- Spring Bank Pharmaceuticals’ (SBPH) Buy Rating Reaffirmed at Chardan Capital (americanbankingnews.com)
NASDAQ:SBPH opened at $14.25 on Friday. The company has a market cap of $196.53, a price-to-earnings ratio of -7.62 and a beta of -0.35. Spring Bank Pharmaceuticals has a fifty-two week low of $7.95 and a fifty-two week high of $18.93.
Several research firms have recently issued reports on SBPH. ValuEngine raised Spring Bank Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $32.00 price objective (up previously from $29.00) on shares of Spring Bank Pharmaceuticals in a research note on Wednesday, February 21st. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $28.00.
WARNING: This piece of content was reported by BBNS and is the property of of BBNS. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://baseballnewssource.com/2018/04/06/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-spring-bank-pharmaceuticals-sbph-stock-price/2029457.html.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.